Add Yahoo as a preferred source to see more of our stories on Google. As SARS-CoV-2 has become endemic At IDWeek 2025, (the joint annual meeting of the Infectious Diseases Society of America, the ...
In an observational study involving nearly 440,000 veterans, both the BNT162b2 vaccine and the mRNA-1273 vaccine were highly effective at preventing infection, hospitalization, and death from Covid-19 ...
A large observational study using US healthcare claims and electronic health record data suggests that Moderna’s updated 2024 ...
CAMBRIDGE, Mass. & BASEL, Switzerland--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new ...
In a randomized, placebo-controlled trial involving children 6 months to 5 years of age, the mRNA-1273 vaccine was shown to be safe, and the elicited antibody responses were similar to those in young ...
CAMBRIDGE, MA / ACCESS Newswire / December 15, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has ...
At least 87 times in the last few months, a health care provider has given a young child the wrong dose of COVID-19 vaccine. COVID mRNA vaccines are associated with a decreased risk of death in ...
The U.S. Food and Drug Administration (FDA) on Saturday approved Moderna, Inc.’s (NASDAQ:MRNA) mNexspike (mRNA-1283), a new vaccine against COVID-19, for all adults 65 and older and individuals aged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback